Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Tenaya Therapeutics. The associated price target remains the same with $3.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Pantginis has given his Buy rating due to a combination of factors tied to Tenaya’s new collaboration with Alnylam and the resulting platform validation. He highlights that pairing Tenaya’s cardiac target discovery engine with Alnylam’s C16 delivery technology meaningfully reduces technical risk, while the upfront funding, cost reimbursement, and reduced late-stage burden help protect Tenaya’s cash runway.
Pantginis also emphasizes the economic potential of the deal, noting up to 15 validated gene targets that collectively represent over a billion dollars in contingent milestones and multiple shots on goal in cardiovascular disease. He further views the strong stock reaction to the announcement as confirmation of investor confidence and underscores that upcoming data from TN-201 and TN-401 remain important additional drivers of value beyond this partnership.